Novo Nordisk's chief scientific officer said the company hopes to bring both oral and subcutaneous formulations of Zenagamtide to market.

Xinhua urged systemwide remediation of intrusive splash-screen advertising, calling for a shift from short-term fixes to sustained regulatory oversight. It said enforcement should move earlier, impose deeper constraints and tougher penalties, and make responsibility explicit across the ad chain—whoever integrates, reviews or operates ads must be held accountable. The commentary singled out covert or fake close buttons, high-sensitivity 'shake-to-redirect' triggers and click-inducement techniques as high-frequency violations requiring strengthened routine monitoring, intensified enforcement and higher penalties to raise the cost of noncompliance. It also called for retrospective inspections of platforms and apps already reported as fixed to prevent recurrence through rebranded ads.

Hong Kong stocks closed higher: the Hang Seng Index rose 1.18% and the Hang Seng Tech Index gained 0.40%. The innovative drug sector led gains; CSPC PHARMA (01093.HK) jumped 7.56% and China Biopharm (01177.HK) rose 8.23%.